NBIX250117P185000
- 0.00
- 0.000.00%
Neurocrine Biosciences Newsroom
What You Can Learn From Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) P/E
Neurocrine Biosciences, Inc. Selects PANTHERxRare Specialty Pharmacy for Distribution of Crenessity (Crinecerfont)
Neurocrine Is Maintained at Overweight by Barclays
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160
Wedbush Raises Price Target on Neurocrine Biosciences to $154 From $148, Keeps Outperform Rating
Barclays Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
Express News | Neurocrine Biosciences Inc : Jefferies Raises Target Price to $168 From $158
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Needham Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating
TD Cowen Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $182
TD Cowen Reaffirms Their Buy Rating on Neurocrine (NBIX)
Neurocrine Biosciences Starts Commercial Sales of New Congenital Adrenal Hyperplasia Treatment
Needham Reiterates Hold on Neurocrine Biosciencesto Hold
Express News | Neurocrine Biosciences Announces Commercial Availability of Crenessity™ (Crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
US MOVERS & SHAKERS Dec 16-Dec 20, 2024
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $185
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $148 to $190
Express News | Neurocrine Biosciences Inc : JP Morgan Raises Target Price to $185 From $184
Summit Therapeutics Shares Are Trading Higher. The Stock May Be Moving in Sympathy With Neurocrine Biosciences Which Received FDA Approval for CRESNESSITY.